Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) can specifically identify tumor cells with EGFR mutations and block the signal transduction pathway of tyrosine protein kinase to promote tumor cell apoptosis (7). Here, EGFR is linked to neoplasm.